Search
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approved[T357] It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. … [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]
Mixtures: OCIDERM-N, CINOLON-NAgalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]
Iroxanadine
go.drugbank.com/drugs/DB05444ExperimentalIt induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC). … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).
Etravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalIn 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg.
Plasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with … [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia).
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalLifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341 … ] Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigational[A19054] It has been widely used for over 50 years,[A299] most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short
Synonyms: 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)Products: Suxamethonium Aguettant 10 mg/ml Injektionslösung in einer FertigspritzeClobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Synonyms: Clobetasol propionate EInternational brands: Embeline EFactor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalFactor XIII (human) is a heat-treated, lyophilized concentrate of coagulation factor XIII, an endogenous enzyme responsible for the crosslinking of fibrin and an essential component of the coagulation … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade.
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigationalMinocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]